Helix Acquisition and BridgeBio Oncology receive SEC approval for merger

Helix Acquisition Corp. II (NASDAQ: HLXB) and BridgeBio Oncology Therapeutics announced that the U.S. Securities and Exchange Commission declared effective their registration statement for a proposed business combination.

The special purpose acquisition company will hold an extraordinary general meeting of shareholders on August 4, 2025, to vote on the merger. The proxy statement will be mailed to Helix shareholders of record as of June 30, 2025.

The companies expect the business combination to close in August 2025, subject to satisfaction of closing conditions. Upon completion, the combined company will be renamed BridgeBio Oncology Therapeutics.

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting RAS and PI3Kα malignancies. The company was initially formed as a subsidiary of BridgeBio Pharma, Inc. (NASDAQ: BBIO).

Helix Acquisition Corp. II is a SPAC sponsored by Cormorant Asset Management that raised $184 million in its initial public offering on February 9, 2024. The company is headquartered in Boston, Massachusetts.

The parties entered into a definitive business combination agreement on February 28, 2025, which was amended on June 17, 2025. The SEC declared the registration statement effective on July 10, 2025.

The registration statement includes a proxy statement and prospectus that will be distributed to Helix shareholders for their consideration of the proposed transaction.

You May Also Be Interested In

• Gores Holdings XI closes $358.8M IPO on Nasdaq
• AMC Robotics leases Vietnam facility for NovaArm production
• Hertz cuts guidance, announces notes and stock offerings, shares sink